Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario.
Carolin KrekelerLea ReitnauerVera Ulrike BacherCyrus KhandanpourLeander StegerGöran Ramin BoeckelJustine KlosnerPhil-Robin TepasseMarcel KemperMarc Tim HenniesRolf MestersMatthias StelljesNorbert SchmitzAndrea KerkhoffChristoph SchliemannJan-Henrik MikeschNicole SchmidtGeorg LenzAnnalen BleckmannEvgenii ShumilovPublished in: Cancers (2022)
Patients with HMs are at a high risk of COVID-19 booster vaccine failure; yet COVID-19 breakthrough infections after prime-boost vaccination are predominantly mild. Booster failure can likely be overcome by passive immunization, thereby providing immune protection against COVID-19 and attenuating the severity of COVID-19 courses. Further sophistication of clinical algorithms for preventing post-vaccination COVID-19 breakthrough infections is urgently needed.